Cardio-Oncology 2022: Cancer Therapeutics-Related Cardio-Vascular Toxicity скачать в хорошем качестве

Cardio-Oncology 2022: Cancer Therapeutics-Related Cardio-Vascular Toxicity

Cardio-Oncology 2022: Cancer Therapeutics-Related Cardio-Vascular Toxicity \ June 01 (Wed), 2022, at 12:00 PM-14:10 PM ( Singapore, Taiwan ), 11:00 AM-13:10 PM ( Thailand ), & 13:00 PM-15:10 PM ( Japan, Korea ). The APSC Cloud webinar will be co-chaired by Prof Dr Hidehiro Kaneko ( Japan ) and President Dr Suphot Srimahachota ( Thailand ). Five Representative Speakers ( also as internal panelists ) from five member Societies of the APSC are Dr Hidehiro Kaneko ( Japan ) Shared risk factors and mechanistic biomarkers between cancer and cardiovascular disease: A window of innovations Dr Chong Jun Hua ( Singapore ) Cardiotoxicity associated with anthracycline antitumor therapy: Incidence. monitoring, and dexrazoxane rescue Dr Yun-Gyoo Lee ( Korea ) Cardiotoxicity and Vascular toxicity associated with VEGF- signaling pathway inhibitors: Bevacizumab versus novel tyrosine kinase inhibitors Dr Wei-Ying Chang ( Taiwan) Cardiotoxicity associated with HER 2 inhibitors for breast cancer: Trastuzumab vs novel dual tyrosine kinase inhibitors Dr Teerapat Yingchoncharoen ( Thailand ) Cardiovascular toxicities associated with immune checkpoint inhibitors: New kid on the rock, with new trouble?